[293 Pages Report] The global clinical diagnostics market is expected to reach a valuation of US$ 126.6 Billion in 2032. With growing popularity of blood tests and other tests through clinical diagnostics, the overall sales of clinical diagnostics products are projected to grow at a robust CAGR of 5.5% between 2022 and 2032, totaling around US$ 74 Billion by the end of 2022.
| Attributes | Details |
|---|---|
| Clinical Diagnostics Market Size (2032) | US$ 126.6 Billion |
| Clinical Diagnostics Market Revenue Forecast (2022) | US$ 74 Billion |
| Clinical Diagnostics Market Growth Rate (2022 to 2032) | 5.5% CAGR |
The process of identifying a disease, condition, or injury based on the signs and symptoms a patient is having and the patient’s health history and physical exam. Further testing, such as blood tests, imaging tests, and biopsies, may be done after a clinical diagnosis is made.
Clinical Diagnostics are medical devices used to perform diagnostic tests on biological samples such as blood, urine, and tissues. These tests help detect and monitor infectious diseases, autoimmune diseases, and several medical conditions that are being used to analyze drug therapies.
In addition, technological advancements such as rapid test kits for Clinical Diagnostics industry have expanded at an astounding rate in recent years and is expected to continue in the future. Clinical diagnostics is applied to various aspects in healthcare.
Furthermore, there has been a rise in use of clinical testing across the globe. This is attributed to surge in awareness toward point-of-care testing. For instance, key players are focused on launching new transportable, portable, and handheld instruments, which can be easily used outside laboratory settings.
Thus, this leads to rise in demand among healthcare professionals and patients. In addition, high sensitivity and specificity associated with in vitro diagnostic testing also plays a major role toward their adoption. Hence, the factors mentioned above contribute to Clinical diagnostics market growth.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
“Rising Prevalence of Chronic Diseases, High Investments in R&D, and Innovations in Clinical Diagnostics Systems Augmenting Clinical Diagnostics Market Growth
As per Future Market Insights, the global demand for clinical diagnostics is anticipated to grow at a healthy CAGR of 5.5% during the forecast period between 2022 and 2032, in comparison to 6.1% CAGR registered from 2015 to 2021.
As per the Non-communicable Diseases Key Facts published by the World Health Organization (WHO), in April 2021, chronic diseases kill around 41 million people each year, which is equivalent to 71% of all deaths worldwide.
Owing to the increase in chronic diseases, the demand for healthcare systems is also increasing. Clinical diagnostics have, thus, proven to be beneficial in chronic disease conditions, and are found to be valuable for disease prevention, detection, and management.
Clinical diagnostics help detect early warning signs and individual risk factors, creating new opportunities for prevention and early intervention. Thus, the increasing incidence of chronic diseases is expected to propel the overall market further.
Growth can be attributed to the increasing adoption of clinical diagnostics, attributed to the rise in testing due to the pandemic. The development of automated clinical diagnostics systems for laboratories and hospitals to provide efficient, accurate, and error-free diagnoses is expected to boost the market growth over the analysis period.
The rising number of clinical diagnostics products being launched by key players is also augmenting the growth of the market. Clinical diagnostics products with molecular diagnostic capabilities deliver effective and accurate results.
The market is expected to grow, owing to the increasing incidence of infectious and chronic diseases and the increasing adoption of automated platforms. The rising number of tests owing to the constant upsurge in patients and funding by governments are the factors that are expected to escalate the demand for COVID-19 test kits and drive the overall market growth exponentially.
The rising demand for point-of-care clinical diagnostics devices and the increasing adoption of these devices have been instrumental in driving the market growth. This is further augmented by increasing investment by key players in research & development to innovate products and explore new applications of clinical diagnostics techniques.
High Cost of Clinical Diagnostics Instruments to Impede Growth in Emerging Countries
Clinical diagnostics products have witnessed significant advancements and developments in the past decade regarding new products being adopted and further design amendments. However, the high cost of Clinical diagnostics instruments and the high cost associated with the maintenance of the instruments have hindered the market growth to a certain extent.
Furthermore, clinical diagnostics instruments require skilled professionals for operation. Thus, this increases the maintenance cost of the device, which ultimately hinders the overall growth of the market.
The cost of RT-PCR systems ranges from USD 15,000 to over USD 90,000. The above cost factors have been responsible for the relatively limited adoption of clinical diagnostics products in several countries and regions.
Principal Consultant
“Rising Prevalence of Cancer and Increasing Need for Early Diagnosis and Detection of Tumors are pushing the Demand for Clinical Diagnostics in the U.S”
The U.S is expected to hold the largest share of US$ 43.8 Billion in the global Clinical Diagnostics Market, and is expected to reach at a CAGR of 5.0% over the analysis period.
Over the years, sales of clinical diagnostics products have risen at a substantial pace across the US and the trend is likely to continue even during the forecast period, owing to the increasing geriatric population, rising patient awareness about the value of laboratory tests, and the rising prevalence of infectious and chronic disease patients.
The increasing number of COVID-19 infections has led to increased funding and an increasing number of testing, which has boosted the overall market growth. For instance, in September 2020, the National Institutes of Health, US, announced its plan to give funding of USD 129.3 million to nine companies, including MatMaCorp, Maxim Biomedical Inc., MicroGEM International, etc., to scale-up manufacturing support for a new set of COVID-19 testing technologies as part of its Rapid Acceleration of Diagnostics (RADx) initiative.
As per the Centers for Disease Control and Prevention (CDC), in the United States, four in ten adults have two or more chronic diseases, and six in ten adults have a chronic disease. Chronic diseases such as cancer, heart disease, and diabetes are the leading causes of death and disability in the United States and are leading drivers of the USD 3.8 trillion spent in annual health care costs.
This has led to a higher demand for better treatment with efficient management, further driving the market in the United States. Hence, the increasing prevalence of infectious and chronic diseases and the growing awareness of the value of laboratory tests are expected to fuel the market growth in the country.
“Increasing Demand for Safe and Noninvasive Imaging Technologies for the Diagnosis of various Diseases Creating Space for the Clinical Diagnostics Market in China”
As per FMI, China is anticipated to be the second-most dominant country in terms of clinical diagnostics market share. The market in China holds a significant share due to rising healthcare expenditure, well-established infrastructure, and a large pool of patients suffering from infectious diseases and cancer.
In addition, the growing population and emerging advancements in technologies are the major factors that are expected to fuel the market growth. The market in China is estimated to grow at the highest CAGR, attributed to the improving approval & reimbursement policies and rising per capita healthcare expenditure in the country.
China is expected to hold the largest share of US$ 9.2 Billion in the global clinical diagnostics market, and is expected to reach at a CAGR of 5.0% over the analysis period.
“Lipid Panel Tests to Grow Exponentially During the Forecast Period”
Based on test, the Lipid Tests Panel of the global clinical diagnostics market is likely to account for the largest share of 5.5%, in the global clinical diagnostics market during the forecast period.
The lipid panel is a blood test that measures the lipids, fats, and fatty substances used as a source of energy by the body. The lipid panel includes tests for total cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, cholesterol/HDL ratio, and non-HDL cholesterol.
Many studies have observed a decrease in total cholesterol, LDL-C, and HDL-C levels in patients with COVID-19 infections. Based on various studies, the decrease in LDL-C and/or HDL-C was more profound with greater severity of the illness.
Therefore, patients with low HDL-C levels during admission to the hospital were at an increased risk of developing a severe disease compared to patients with high HDL-C levels, which has boosted the test demand. With the recovery from COVID-19, the serum lipid levels return to levels present before infection.
A lipid panel measures the level of specific lipids in blood to assess the risk of cardiovascular disease and is used in screening populations to identify subjects with a high risk of developing a cardiac event.
According to Cardiovascular Diseases Key Facts published by the World Health Organization, in June 2021, cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for around 32% of all global deaths. Moreover, over three-quarters of CVD deaths take place in middle- and low-income countries.
Hence, with an increase in the prevalence and mortality rate of cardiovascular diseases, there is an increase in the requirement of lipid profile testing at an early stage, which is driving the lipid panel segment. Key companies are focusing on novel product developments and launches to leverage potential opportunities. Hence, the segment is estimated to grow over the forecast period due to the aforementioned factors.
“Instruments to Remain the Most Lucrative Product Type of Clinical Diagnostics Systems”
Future Market Insights’ latest clinical diagnostics market forecast estimates the instruments segment to grow at a CAGR of 5.0% during the assessment period. Growth of this segment is attributed to the continuous innovations in the instruments used in the process of the Clinical Diagnostics.
Additionally, rising adoption of advanced instruments in the setting, along with rapid investments by public and private sectors in laboratory infrastructure in developing countries is another factor that is expected to boost the segment’s growth over the analysis period.
Furthermore, most complex and sensitive diagnostic tests are carried out in laboratories and require skilled lab staff, specialized equipment, and slightly more time to run.
The instruments segment is projected to grow at a substantial CAGR during the forecast period. Due to the increased burden of patient populations suffering from various diseases (diabetes, infectious disease, HIV), medical device giants are focusing on introducing innovative and accurate testing kits.
“Demand for Clinical Diagnostics Products to Remain High in Hospital Laboratory Segment”
As per FMI, the hospital laboratory segment is anticipated to account for the largest share of the clinical diagnostics market in 2022. Factors such as rapid rise in the number of hospital laboratories worldwide, increasing frequency of patient visits to hospitals, and escalating government efforts to make various treatments and diagnostic technologies available in hospitals are spurring the growth of this segment.
Emerging clinical diagnostics market trends indicate the hospital laboratory segment to grow at the highest CAGR during the assessment period between 2022 and 2032.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
There are many prominent market players in the clinical diagnostics market, who are working hand-in-hand to provide the best-in-class Clinical Diagnostics for enhancing the global arena. However, there are many global start-ups in the clinical diagnostics market, who are stepping forward in matching the requirements of the clinical diagnostics domain.
Global Startups of Clinical Diagnostics Market
Some of the leading clinical diagnostics service providers include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Siemens AG, Hologic Inc., Qiagen NV, Hoffmann-La Roche AG, Thermo Fisher Scientific, Quest Diagnostics Inc., and Charles River Laboratories, among others.
These key clinical diagnostics system providers are adopting various strategies such as new product launches and approvals, partnerships, collaborations, acquisitions, mergers, etc. to increase their sales and gain a competitive edge in the global clinical diagnostics market.
For instance,
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 5.5% from 2022 to 2032 |
| Market Value in 2022 | US$ 74 Billion |
| Market Value in 2032 | US$ 126.6 Billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in US$ Million, Volume in Kilotons and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The global clinical diagnostics market is expected to reach US$ 126.6 Billion in 2032
As per Future Market Insights, the clinical diagnostics industry is expected to grow at a CAGR of 5.5% throughout the forecast period (2022-2032).
The clinical diagnostics systems market is anticipated to reach a valuation of US$ 74 Billion by 2022
The U.S is the most lucrative market for clinical diagnostics systems, registering a 5% CAGR until 2032
China is forecast to accumulate a market value of US$ 9.2 Billion by the end of the 2022-2032 period of assessment
Clinical diagnostics instruments are anticipated to be the most demanded, growing at a CAGR of 5%
1. Executive Summary 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Clinical Diagnostic 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Bn) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Market, by Key Countries 4.2. Market Opportunity Assessment (US$ Bn) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Growth in Automation, By Country 4.5.3. Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Market Demand Analysis 2015-2021 and Forecast, 2022-2032 6.1. Historical Market Analysis, 2015-2021 6.2. Current and Future Market Projections, 2022-2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Market Value Analysis 2015-2021 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Bn) Analysis, 2015-2021 7.2. Current and Future Market Value (US$ Bn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Test 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Bn) Analysis By Test, 2015-2021 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Test, 2022-2032 8.3.1. Lipid Panel 8.3.2. Liver Panel 8.3.3. Renal Panel 8.3.4. Complete Blood Count 8.3.5. Electrolyte Testing 8.3.6. Infectious Disease Testing 8.3.7. Other Tests 8.4. Market Attractiveness Analysis By Test 9. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Bn) Analysis By Product, 2015-2021 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2022-2032 9.3.1. Instruments 9.3.2. Reagents 9.3.3. Other Products 9.4. Market Attractiveness Analysis By Product 10. Global Market Analysis 2015-2021 and Forecast 2022-2032, By End-user 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Bn) Analysis By End-user, 2015-2021 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By End-user, 2022-2032 10.3.1. Hospital Laboratory 10.3.2. Diagnostic Laboratory 10.3.3. Point-of-care Testing 10.3.4. Other End Users 10.4. Market Attractiveness Analysis By End-user 11. Global Market Analysis 2015-2021 and Forecast 2022-2032, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Bn) Analysis By Region, 2015-2021 11.3. Current Market Size (US$ Bn) & Analysis and Forecast By Region, 2022-2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. Asia Pacific 11.3.5. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2015-2021 and Forecast 2022-2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2015-2021 12.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032 12.4.1. By Country 12.4.1.1. U.S. 12.4.1.2. Canada 12.4.1.3. Rest of North America 12.4.2. By Test 12.4.3. By End-user 12.4.4. By Product 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Test 12.5.3. By End-user 12.5.4. By Product 13. Latin America Market Analysis 2015-2021 and Forecast 2022-2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2015-2021 13.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032 13.4.1. By Country 13.4.1.1. Brazil 13.4.1.2. Mexico 13.4.1.3. Rest of Latin America 13.4.2. By Test 13.4.3. By End-user 13.4.4. By Product 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Test 13.5.3. By End-user 13.5.4. By Product 14. Europe Market Analysis 2015-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2015-2021 14.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. Germany 14.4.1.2. France 14.4.1.3. U.K. 14.4.1.4. Italy 14.4.1.5. Benelux 14.4.1.6. Nordic Countries 14.4.1.7. Rest of Europe 14.4.2. By Test 14.4.3. By End-user 14.4.4. By Product 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Test 14.5.3. By End-user 14.5.4. By Product 15. Asia Pacific Market Analysis 2015-2021 and Forecast 2022-2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2015-2021 15.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032 15.4.1. By Country 15.4.1.1. China 15.4.1.2. Japan 15.4.1.3. South Korea 15.4.1.4. Rest of Asia Pacific 15.4.2. By Test 15.4.3. By End-user 15.4.4. By Product 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Test 15.5.3. By End-user 15.5.4. By Product 16. Middle East and Africa Market Analysis 2015-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2015-2021 16.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. South Africa 16.4.1.3. Turkey 16.4.1.4. Rest of Middle East and Africa 16.4.2. By Test 16.4.3. By End-user 16.4.4. By Product 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Test 16.5.3. By End-user 16.5.4. By Product 17. Key Countries Market Analysis 2015-2021 and Forecast 2022-2032 17.1. Introduction 17.1.1. Market Value Proportion Analysis, By Key Countries 17.1.2. Global Vs. Country Growth Comparison 17.2. US Market Analysis 17.2.1. Value Proportion Analysis by Market Taxonomy 17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.2.2.1. By Test 17.2.2.2. By End-user 17.2.2.3. By Product 17.3. Canada Market Analysis 17.3.1. Value Proportion Analysis by Market Taxonomy 17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.3.2.1. By Test 17.3.2.2. By End-user 17.3.2.3. By Product 17.4. Mexico Market Analysis 17.4.1. Value Proportion Analysis by Market Taxonomy 17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.4.2.1. By Test 17.4.2.2. By End-user 17.4.2.3. By Product 17.5. Brazil Market Analysis 17.5.1. Value Proportion Analysis by Market Taxonomy 17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.5.2.1. By Test 17.5.2.2. By End-user 17.5.2.3. By Product 17.6. Germany Market Analysis 17.6.1. Value Proportion Analysis by Market Taxonomy 17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.6.2.1. By Test 17.6.2.2. By End-user 17.6.2.3. By Product 17.7. France Market Analysis 17.7.1. Value Proportion Analysis by Market Taxonomy 17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.7.2.1. By Test 17.7.2.2. By End-user 17.7.2.3. By Product 17.8. Italy Market Analysis 17.8.1. Value Proportion Analysis by Market Taxonomy 17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.8.2.1. By Test 17.8.2.2. By End-user 17.8.2.3. By Product 17.9. BENELUX Market Analysis 17.9.1. Value Proportion Analysis by Market Taxonomy 17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.9.2.1. By Test 17.9.2.2. By End-user 17.9.2.3. By Product 17.10. UK Market Analysis 17.10.1. Value Proportion Analysis by Market Taxonomy 17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.10.2.1. By Test 17.10.2.2. By End-user 17.10.2.3. By Product 17.11. Nordic Countries Market Analysis 17.11.1. Value Proportion Analysis by Market Taxonomy 17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.11.2.1. By Test 17.11.2.2. By End-user 17.11.2.3. By Product 17.12. China Market Analysis 17.12.1. Value Proportion Analysis by Market Taxonomy 17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.12.2.1. By Test 17.12.2.2. By End-user 17.12.2.3. By Product 17.13. Japan Market Analysis 17.13.1. Value Proportion Analysis by Market Taxonomy 17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.13.2.1. By Test 17.13.2.2. By End-user 17.13.2.3. By Product 17.14. South Korea Market Analysis 17.14.1. Value Proportion Analysis by Market Taxonomy 17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.14.2.1. By Test 17.14.2.2. By End-user 17.14.2.3. By Product 17.15. GCC Countries Market Analysis 17.15.1. Value Proportion Analysis by Market Taxonomy 17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.15.2.1. By Test 17.15.2.2. By End-user 17.15.2.3. By Product 17.16. South Africa Market Analysis 17.16.1. Value Proportion Analysis by Market Taxonomy 17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.16.2.1. By Test 17.16.2.2. By End-user 17.16.2.3. By Product 17.17. Turkey Market Analysis 17.17.1. Value Proportion Analysis by Market Taxonomy 17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.17.2.1. By Test 17.17.2.2. By End-user 17.17.2.3. By Product 17.17.3. Competition Landscape and Player Concentration in the Country 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Concentration 18.3. Market Share Analysis of Top Players 18.4. Market Presence Analysis 18.4.1. By Regional footprint of Players 18.4.2. Product footprint by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. Abbott Laboratories 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Sales Footprint 19.3.1.4. Strategy Overview 19.3.2. Becton, Dickinson and Company 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Sales Footprint 19.3.2.4. Strategy Overview 19.3.3. BioMerieux 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Sales Footprint 19.3.3.4. Strategy Overview 19.3.4. Bio-Rad Laboratories Inc. 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Sales Footprint 19.3.4.4. Strategy Overview 19.3.5. Danaher Corporation 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Sales Footprint 19.3.5.4. Strategy Overview 19.3.6. Siemens AG 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Sales Footprint 19.3.6.4. Strategy Overview 19.3.7. Hologic Inc. 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Sales Footprint 19.3.7.4. Strategy Overview 19.3.8. Qiagen NV 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Sales Footprint 19.3.8.4. Strategy Overview 19.3.9. Hoffmann-La Roche AG 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Sales Footprint 19.3.9.4. Strategy Overview 19.3.10. Thermo Fisher Scientific 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Sales Footprint 19.3.10.4. Strategy Overview 19.3.11. Quest Diagnostics Inc. 19.3.11.1. Overview 19.3.11.2. Product Portfolio 19.3.11.3. Sales Footprint 19.3.11.4. Strategy Overview 19.3.12. Sysmex Corporation 19.3.12.1. Overview 19.3.12.2. Product Portfolio 19.3.12.3. Sales Footprint 19.3.12.4. Strategy Overview 19.3.13. Sonic Healthcare Ltd 19.3.13.1. Overview 19.3.13.2. Product Portfolio 19.3.13.3. Sales Footprint 19.3.13.4. Strategy Overview 19.3.14. Charles River Laboratories 19.3.14.1. Overview 19.3.14.2. Product Portfolio 19.3.14.3. Sales Footprint 19.3.14.4. Strategy Overview 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Clinical Diagnostics Market
